Osilodrostat treatment was found to be associated with a rapid and sustained reduction in mean concentration of urinary free cortisol and improved clinical symptoms in patients with Cushing’s disease.
Patients with Cushing syndrome are at an increased risk for infections, including severe COVID-19, due to immunodeficiency and other comorbidities.
High-resolution peripheral quantitative computed tomography can be used to assess bone abnormalities in patients with adrenal incidentaloma.
In patients with classical congenital adrenal hyperplasia, the use of modified-release hydrocortisone may improve biochemical control.
Primary aldosteronism is prevalent and increases in parallel with hypertension severity.
Isturisa is exclusively available through the R.A.R.E.™ Patient Support Program and distributed via AnovoRx specialty pharmacy.
In patients with autoimmune Addison disease, there is a rapid decline in steroidogenic capacity once replacement glucocorticoid medication is started.
Patients taking glucocorticoids are at a high risk if they are infected with SARS-CoV-2, according to an editorial article from the Endocrine Society.
The increased mortality rate in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is mostly related to endocrine and metabolic diseases, infections, and oral and esophageal malignancies.
The most clinically appropriate mode of hydrocortisone administration during major stress in patients with adrenal insufficiency is continuous intravenous hydrocortisone.
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.